We invite you to review the following list of funding opportunities related to COVID-19.  This information is abstracted for brevity; please refer to the sponsor’s website for complete information.

 

National Institutes of Health:

*NEW* Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed) (RFA-AG-21-035)

Application due date is June 9, 2021.

  • The purpose of this Cooperative Resource-Related Research Project FOA is to establish a coordinating center to support and develop research, dissemination, and various data sharing activities for social, behavioral, and economic research on COVID-19. The Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (SBECCC) will foster innovation, collaboration, and synergies across researchers funded through the Social, Behavioral and Economic Research on COVID-19 Consortium (U01) program and other relevant NIH-funded studies by supporting networking activities intended to advance research in the field; supporting the development and use of harmonized COVID-19 data constructs for primary and secondary data to support comparability and replicability; assisting in efficient and enhanced sharing/discoverability of data; and disseminating findings to the research community and the public.

*NEW* Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional) (RFA-OD-21-008)

Application due date: July 7, 2021

  • The National Institutes of Health (NIH) are issuing this funding FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This FOA provides an expedited funding mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this program is provided from the American Rescue Plan Act of 2021.

*NEW* Emergency Award: RADx-UP – Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional) (RFA-OD-21-009)

Application due date: July 7, 2021

  • This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021 .

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium  (PAR-21-213)

Letter of Intent due dates: May 9, 2021; October 8, 2021; Expiration Date is November 9, 2021

  • The purpose of this FOA is to advance research on the impact of COVID-19 and associated mitigation efforts on individual, family, and community behavior, as well as research on how subsequent economic disruption affects health-related outcomes. Emphasis should be placed on addressing these questions in underserved and vulnerable populations (see Definitions above). Health effects/outcomes studied are not limited to direct effects of infection and can/should consider indirect and secondary effects of the pandemic. Priority research questions include but are not limited to the following:
  • Behavioral and social factors contributing to SARS-CoV-2 transmission and prevention, such as individual, family, community, and environmental influences that shape adherence to and transmission reduction from coronavirus mitigation behaviors including COVID-19 vaccination.
  • The integration of economic feedback to mitigation policies and behaviors affecting estimates of transmission/prevention. The impact of timing and design of state and local government mitigation policies on differentially affected transmission.
  • How communication disorders or use of hearing aids, American Sign Language, or associative and augmentative communication (AAC) devices impact the likelihood of contracting the SARS-COVID-2, suffering adverse effects from infections, or management of mitigation protocols.
  • Leveraging and integrating data from large cohort studies for the development of machine learning algorithms and other novel methods for prediction models of COVID-19 transmission as well as impact of interventions on transmission.
  • The impact of public health interventions to mitigate COVID-19 transmission on preventive care delivery and use (e.g., mental health care, drug/alcohol use treatment, well-visits, vaccinations, other routine preventive care) and the quantified effects on health.
  • The impact of the pandemic and the concomitant public health response on the management of chronic conditions and disabilities (e.g., cardiovascular disease, HIV, autism, individuals with spinal cord injuries), including effects on self-management of illnesses and relevant health behaviors (e.g., diet, sleep, physical activity, medication adherence, health-monitoring).
  • How the pandemic and associated mitigation policies have affected care of patients with in-person care needs (e.g., persons with dementia) and their caregivers.
  • The impact of the pandemic and concomitant public health response on the management of pregnancy and the post-partum period, including access to healthcare, self-management of health behaviors, and the impact on maternal mortality and morbidity, and pregnancy outcomes, including the management and development of pre-term and other medically fragile infants.
  • How school closures and alternative educational approaches in response to the coronavirus pandemic have affected child development and learning in the short- and long-term, including among children with physical and psychological disabilities; and how school closures have impacted parental functioning and behavioral health (e.g., stress, substance use, etc.).
  • Shifts in modes of healthcare (e.g., telemedicine) and how these shifts are impacting health outcomes.
  • Access to telehealth as a function of health disparities and vulnerability, and the impact of differential access on mental health and substance use-related concerns.
  • The underlying mechanisms linking the pandemic and mitigation strategies with mental and behavioral disorders.
  • The effect of public health mitigation efforts on family- and community-level outcomes, including but not limited to the prevalence of interpersonal violence in families; changes in prevalence of poverty at the community/county/state level; behavioral health symptoms including but not limited to depression, anxiety, and substance use; and the interaction between these various phenomena.
  • The consequences on individual and community health of policies and programs whose primary intention may not have been to address health outcomes (e.g., economic stimulus).
  • Assessment of differential death rates because of COVID that consider biological and social determinants of health.
  • The efficacy of communication to vulnerable populations about preventative health measures (e.g., hand washing, mask wearing, physical distancing, testing, vaccines) and associated adherence outcomes: what modes of communication are most effective and why?
  • Relevant approaches may include but are not limited to:
    • Development of computational, statistical, and mathematical models for the spread and outcomes of COVID-19 and results of possible interventions, including incorporation of economic models related to health and well-being.
    • “Natural experiments” making use of time and place differences in policies, programs, economic circumstances, and other exogenous factors to identify causal factors.
    • Linking of large datasets and nationally representative surveys to assess mortality, comorbidity, and healthcare utilization differentials across sex/gender, racial/ethnic, urban/rural, and socioeconomic lines.
    • Development of statistical models to predict immediate, mid-, and long-term health and economic outcomes across individuals’ lifespan.
    • Leveraging of new data sources (e.g., sensors), data integration (especially at multiple levels of influence), and artificial intelligence and computational modeling.

Notice of Special Interest: Effects of smoking and vaping on the risk and outcome of COVID-19 infection (NOT-DA-20-084)

Expiration date is September 8, 2024; First Available Due Date is January 4, 2021

Health Services Research on Minority Health and Health Disparities (R01 – Clinical Trial Optional) PAR-20-310

Application Due Dates: November 27, 2020; March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023. Expiration Date is March 28, 2023.

Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract (NOT-HD-20-021)
Expiration date is 07/16/2023; First Available due date is 10/05/2020.

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
Expiration date is 9/1/2021; First Available due date is 9/01/2020